TICLID (ticlopidine hcl) is indicated

• to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because TICLID (ticlopidine hcl) is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (see BOXED WARNING and WARNINGS), TICLID (ticlopidine hcl) should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy.
• as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see Clinical Trials).

Stroke: The recommended dose of TICLID (ticlopidine hcl) is 250 mg bid taken with food. Other doses have not been studied in controlled trials for these indications.

Coronary Artery Stenting: The recommended dose of TICLID (ticlopidine hcl) is 250 mg bid taken with food together with antiplatelet doses of aspirin for up to 30 days of therapy following successful stent implantation.

TICLID (ticlopidine hcl) is available in white, oval, film-coated 250-mg tablets, printed in blue with Ticlid (ticlopidine hcl) on one side and 250 on the other. They are provided in unit of use bottles of 30 tablets (NDC 0004-0018-23) and 60 tablets (NDC 0004-0018-22) and 500 tablets (NDC 0004-0018-14).

Store at 15° to 30°C (59°to 86°F)

Distributed by: Roche Pharmaceuticals, Roche Laboratories Inc., 340 Kingsland Street, Nutley, New Jersey 07110-1199. Revised: March 2001. FDA revision date: 4/18/2001

Last reviewed on RxList: 6/10/2008
This monograph has been modified to include the generic and brand name in many instances.